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Migraine is a paroxysmal pain disorder managed with abortive therapy during a pain 
attack, prophylactic therapy to prevent attacks, and often a combination of both. Calcitonin gene-
related peptide (CGRP) and its receptor have a role in the provocation of migraines, and 
therefore have been targeted in the development of both preventive and abortive therapies. 
However, there is limited research investigating concomitant use of the therapies. This study will 
examine the safety and efficacy of oral rimegepant when used for acute treatment concomitantly 
with a monoclonal antibody (mAb) targeting the CGRP ligand or receptor for the preventive 
treatment of migraine. A biphasic trial with a randomized, double-blind, placebo-controlled 
Primary Phase and an open label Secondary Phase will assess efficacy as measured by freedom 
from pain at 2 hours. The results of this study have the potential to improve and expand the 
management approaches used for migraine patients. 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
 
Migraine is a disabling disorder which is estimated to affect approximately 15% of the 
global population.1 Migraine is characterized by a painful unilateral headache attack often 
associated with nausea, vomiting, photophobia, and phonophobia.2 An increased frequency of 
migraine headache days correlates with increased disability and results in decreased quality of 
life involving both negative social and psychological impacts.3  
Although the definitive underlying pathophysiology of migraine is unknown, the 
inflammatory peptide, calcitonin gene-related peptide (CGRP), and its receptor, expressed in 
both the peripheral and central nervous system including trigeminovascular pathways, have been 
identified as having a role in the provocation of migraines.4 This system has been targeted in the 
search for new efficacious and safe migraine treatments. One of the more promising classes are 
small molecule CGRP receptor antagonists, also called gepants. Such a small molecule 
antagonist can either compete with the initial CGRP C-terminal binding event and block the 
activation of the receptor or potentially displace bound CGRP and deactivate the receptor.5 One 
of the gepants, rimegepant (Nurtec-ODT [Biohaven Pharmaceuticals, New Haven, CT]), was 
found to be significantly more effective than placebo for acute treatment of migraine, as 
measured by pain freedom and reduction of most bothersome symptom (MBS) two hours after 
intake.2 It was approved for acute treatment of migraine by the Food and Drug Administration 
(FDA) in February 2020 (Biohaven Pharmaceutical Company Holding Ltd., 2020).  
The advent and approval of rimegepant was a significant development in the acute 
treatment of migraine. Although many abortive treatments for migraine are available, their 
efficacy and tolerability vary greatly among migraine patients. One of the more widely and well-
established acute treatments are triptans. Sumatriptan is the most commonly used acute treatment 
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for migraine attacks in the United States of America (US).6 However, pain freedom at 2 hours 
after drug intake, the primary outcome in most clinical trials for acute treatment of migraine, is 
only experienced by 12-40% of patients depending on the triptan used.2 Also, triptans are 
contraindicated in patients with coronary artery disease, uncontrolled hypertension, and 
cerebrovascular disease.5 The gepants’ proposed mechanism of action involves the inhibition of 
vasorelaxant responses to CGRP in the middle meningeal arteries, and they are less potent in 
antagonizing the vasodilatory responses in the coronary arteries.2,7,8 Therefore, rimegepant may 
be a suitable alternative for patients who are unable to use or do not currently achieve pain 
freedom from triptans or other abortive treatments. It continues to be important to consider the 
natural cardioprotective effects of CGRP as well as any pre-existing cardiovascular or 
cerebrovascular risk factors when using drugs that target this system. 
The CGRP system has also become a target for preventive migraine therapy. Several new 
preventive interventions have been introduced and are increasingly being utilized by patients 
with migraine. The primary focus involves monoclonal antibodies (mAbs) that target the CGRP 
system and unlike other existing preventives, are administered via monthly injection (or 
quarterly injection for fremanezumab [Ajovy] and eptinezumab [Vyepti]). These FDA approved 
preventives include erenumab-aooe (Aimovig [Amgen, Thousand Oaks, CA and Novartis, 
Switzerland]), galcanezumab-gnlm (Emgality [Eli Lilly, Indianapolis, IN]), fremanezumab-vfrm 
(Ajovy [Teva, Israel]), and eptinezumab-jjmr (Vyepti [Lundbeck Seattle Biopharmaceuticals, 
Inc., Bothell, WA] which have all demonstrated safety and efficacy in trials.9-12 Galcanezumab, 
fremanezumab, and eptinezumab neutralize some portion of circulating α-CGRP and β-CGRP 
ligands which prevent it from signaling.5 Erenumab is unique from the other CGRP preventives 
in that it blocks the CGRP receptor instead of the peptide itself.13 Erenumab and fremanezumab 
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are approved for prevention in adults with either the episodic (<15 migraine days per month) or 
chronic (>14 migraine days per month) form of migraine. Fremanezumab has also demonstrated 
efficacy in patients with documented failure of up to four migraine preventive medication 
classes.11 Galcanezumab is approved for migraine prevention in those with at least four 
migraines per month and it is the only CGRP mAb that is approved for cluster headache 
prevention.13 In contrast to the other CGRP mAbs that are injected subcutaneously, eptinezumab 
is administered intravenously every 3 months and approved for the episodic or chronic form of 
migraine.12,14 The advent of this new class of preventive treatment in migraine is welcomed by 
both patients and providers. Existing preventive options for migraine consist of a variety of 
antihypertensive, antidepressant, and antiepileptic medications, which have numerous side 
effects and on which less than 50% of patients experience a 50% or greater reduction in their 
monthly attack frequency.4 The CGRP mAbs also have ranged from 43-62% of patients 
achieving 50% reduction, but the ease of intermittent dosing as well as low incidence and mild to 
moderate severity of reported adverse events make them a desirable alternative.4,13 Furthermore, 
CGRP antibodies show a low risk for drug-drug interactions and hepatotoxicity, which can be 
important for patients using multiple medications.4 Complete remission from migraine is 
uncommon, even with this breakthrough preventive treatment, and acute migraine attacks will 
still occur in the majority of patients on CGRP antibody therapy. Although at a reduced 
frequency and intensity, these remaining attacks are often debilitating and require acute 
treatment.15  
1.2 Statement of the Problem 
 
Given the concomitant development of gepants and mAbs, both of which act on the CGRP 
system, it begs the questions—Would patients using both experience greater benefit? Is such a 
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combination safe? Targeting the CGRP system for both acute and prophylactic migraine 
treatment has the potential to generate a stronger antimigraine effect, however, a possible 
increase in side effects would have to be thoroughly assessed as well.2 Published reports of the 
concomitant use of oral rimegepant for acute treatment and a mAb for prevention are limited. A 
small case series demonstrated possible efficacy in treating refractory migraine with concomitant 
rimegepant and erenumab.16 Following those promising cases, an open-label sub-study of 13 
migraine patients simultaneously using rimegepant with erenumab or either anti-CGRP mAbs, 
fremanezumab or galcanezumab, showed no serious adverse events; efficacy was not reported, 
however.17 Therefore, further study in the form of a randomized controlled trial to investigate the 
safety and efficacy of rimegepant in the setting of concomitant mAb therapy is necessary. If 
shown to be effective as well as safe, this therapeutic approach may have clinical implications 
for migraine treatment. Exploration of concomitant CGRP therapy may provide the best 
opportunity to expand evidence-based migraine management and to improve quality of life in 
migraine patients. 
1.3 Goals and Objectives 
 
The goal of this study is to investigate the efficacy and safety of rimegepant for acute 
migraine treatment when used concomitantly with a CGRP ligand- or receptor-targeted mAb 
compared to use without a mAb. Efficacy will be determined by freedom from pain at 2 hours 
after administration of rimegepant. 
1.4 Hypothesis 
 
When using rimegepant as an abortive intervention, adult subjects on an anti-CGRP or 
anti-CGRP receptor mAb preventive (subcutaneous or intravenous injection) will have a 
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different incidence proportion of freedom from pain at 2 hours compared to those who have 
never used a mAb preventive. 
1.5 Definitions 
 
• Rimegepant: CGRP receptor antagonist, single dose 75 mg oral dissolving tablet 
• Adult: ages 18-65 (inclusive) 
• Anti-CGRP or anti-CGRP receptor monoclonal antibody migraine preventives: 
erenumab, galcanezumab, fremanezumab, or eptinezumab 
• Freedom from pain: On a 0 to 3 pain severity numerical rating scale (0=none, 1=mild, 
2=moderate, 3=severe), the reduction from moderate (2) or severe (3) at the time of drug 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
During the period of July 2020 to July 2021, a comprehensive systematic literature search 
was conducted using repeated searches of PubMed, Scopus, Web of Science, and 
clinicaltrials.gov databases. Assistance was much appreciated and provided by the librarians at 
the Yale School of Medicine. Searches were conducted using the following combination of 
MeSH terms: “migraine”, “calcitonin gene-related peptide”, “CGRP”, “gepant[s]”, 
“rimegepant”, “monoclonal antibod[y][ies]”, “erenumab”, “galcanezumab”, “fremanezumab”, 
“eptinezumab”, and included brand and alternative names for each medication. Reference lists of 
all studies were looked at to identify additional pertinent literature. In this review, relevant 
clinical studies (including case series and conference poster presentations), systematic reviews, 
and meta-analyses were included. Preference was given to articles detailing concomitant use of 
CGRP monoclonal antibodies (mAbs) and rimegepant, and randomized controlled trials (RCTs) 
investigating efficacy of rimegepant. 
 The literature search demonstrates the novelty of concomitant use of rimegepant with 
CGRP mAb therapy. Empirical studies documenting their use are inherently limited due to being 
case series. For this reason, RCTs investigating efficacy of the medications and the classes to 
which they belong to were also included to obtain the maximal amount of information existing 
around their clinical use thus far. The novelty of the medications establishes opportunities for 
research, however this also reveals the necessity of designing a study which is both feasible and 
realistic for the stage at which the drugs can be safely studied. Without advancing to a RCT to 
investigate the concomitant use of the medications, there will be a lack of data to support clinical 
benefit, thus justifying the need for the proposed study. 
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2.2 Mechanisms of CGRP Blockade 
Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide that binds to a 
CGRP receptor and causes potent vasodilation, including in cranial vasculature and specifically 
within the trigeminal ganglion.1 The peptide is known to be released during migraine attacks and 
intravenous infusions of CGRP have been shown to induce migraine-like headaches in migraine 
patients.2 It has been proposed that elevated levels of CGRP may lead to sensitization of 
neuronal circuits such that usual sensory inputs (light, sounds, tastes, odors) are experienced as 
bothersome.3 The mAbs likely target CGRP and its receptors within the trigeminal ganglion and 
due to their molecular weight of 150 kilo Daltons (kDa) and structure they are unlikely to cross 
the blood brain barrier (BBB).1-3 Although gepants weigh 0.2-1 kDa, their main target is also 
thought to be outside of the BBB since only a small percentage of gepant is detected in 
cerebrospinal fluid compared to plasma following administration in non-human primates.2 
 The CGRP receptor is a G-protein-coupled receptor which is formed by calcitonin 
receptor-like receptor (CLR) and a receptor activity-modifying protein 1 (RAMP1), therefore it 
is often referred to as CLR/RAMP1 receptor.3 Rimegepant is a small molecule antagonist with 
two proposed mechanisms: competition with the initial binding of CGRP to its receptor, blocking 










Figure 1. Mechanisms of CGRP blockade by a small molecule CGRP Receptor Antagonist (dark blue): competition 
with the initial CGRP ligand (red) C-terminal binding event, preventing N-terminal agonist insertion (D to F), and 
displacement of bound CGRP ligand (E to F).3  
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In order to achieve efficacy with either proposed mechanism, high enough circulating plasma 
levels are needed as well as balanced physical properties of receptor affinity, protein binding, 
pharmacokinetics, and safety.3 In these regards, rimegepant has been optimized. For example, its 
standard oral dissolving tablet (ODT) formulation has been shown to accelerate relief of 
migraine through more rapid exposure, showing difference of effect from placebo as early as 15 
minutes following administration and statistically significant by 1 hour for pain relief and return 
to normal function.3 From a safety perspective, the increased potency of rimegepant in 
antagonizing the CGRP receptors in the middle meningeal arteries as compared to the coronary 
arteries may prevent cardiovascular side effects and allow for a broadened patient population to 
use them in comparison to triptans.2,4,5  
 The migraine preventive mAb, erenumab, binds with high affinity to and antagonizes the 
CLR/RAMP1 receptor, while galcanezumab, fremanezumab, and eptinezumab bind to the 
neuropeptide itself, neutralizing some portion of the ligand preventing it from signaling through 
the CLR/RAMP1 receptor.3,6 The mAbs’ high selectivity for either CGRP or the CGRP receptor 
reduces the risk of off-target effects and possible drug to drug interactions. They also have a very 
long plasma half-life, allowing for once monthly or quarterly injection.2 Given that they are 
tolerated well with infrequent administration, this leads to higher treatment adherence rates 
compared to other preventives.7 Also, the long half-life of the monoclonal antibodies may target 
the high levels of CGRP associated with medication overuse headache, a fairly common problem 
among migraine patients, and alleviate this as well.2 Unfortunately, the intended preventive 
effect varies among patients, where some have no response, some have a small reduction in their 
number of monthly headache days, and some have a near or actual complete response.2 In a large 
trial investigating efficacy of erenumab, 40% of participants achieved >50% reduction in 
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monthly migraine days, and no participants were rid of migraine attacks entirely.7 Given this, 
acute treatment will still be required and herein lies an opportunity to investigate the concomitant 
use of gepants and mAbs. 
2.3 Concomitant Use of Gepants and Monoclonal Antibodies (mAbs) 
Especially for difficult-to-treat patients, a possible therapeutic approach has emerged 
involving the combination of gepants and monoclonal antibodies (mAbs).8 Acting on the CGRP 
pathway in two ways, there’s potential for a stronger anti-migraine effect. For example, it’s 
possible that surges of CGRP during migraine attacks may be better targeted by the small 
molecule gepants with quicker onset of action and short half-life while the biologic mAbs’ 
longer half-life offer sustained migraine prevention.3 The medications offer differentiation in 
their action and therefore increase coverage for the migraine patient. However, combination 
treatment may have potential limitations which would need to be considered in the design of the 
present trial. Not all patients have the same degree of response to receptor or peptide blockade 
offered by mAb preventives, so it would be plausible to expect similar variation in response to 
antagonism of the CGRP receptor with rimegepant.9 To better characterize the response to 
combination therapy, one stratified analysis would compare the response to rimegepant seen in 
positive versus less positive responders to preventive mAbs. Another potential mechanistic 
conflict to consider is that with blocking of the CGRP receptor, CGRP can still bind other 
receptors (e.g., amylin receptor 1, AMY1) and induce a migraine effect. Conversely, if the 
CGRP neuropeptide is blocked, it is still possible for other peptides (e.g., adrenomedullin) to 
activate the CGRP receptor albeit with lower affinity than CGRP.2 Both proposed conflicts, if 
true, would preclude optimal migraine management. Lastly, the chronic blockade of the CGRP 
receptor could result in a compensatory overexpression of CGRP receptors leading to tolerance 
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of the medications over time.4 These possible barriers will not be elucidated in this proposed 
trial, however being aware of the potential shortcomings, as well as the strengths, of a treatment 
modality on a molecular level is essential when expanding this area of study.  
Two case series exist describing the potential for concomitant use of a CGRP mAb and 
CGRP receptor antagonist in the treatment of migraine. In this first example, a case series 
presents two subjects participating in a long-term safety study of rimegepant for acute treatment 
(after FDA approval); both were started on monthly erenumab in addition to existing 
rimegepant.10 Both subjects self-reported decades of medically refractory migraine. While on 
erenumab, every migraine attack the subjects treated with rimegepant was successfully relieved 
and no other acute rescue medications were required.10 More so, no adverse events were 
experienced by either subject. This study, although purely observational and limited by size, was 
a breakthrough in that it brought forth the reasonable possibility that CGRP signaling could be 
targeted acutely (i.e., by a gepant) on a background of chronic inhibition (i.e., by a mAb). It is 
theorized the 2 agents differ in half life and potency, allowing rimegepant to provide additional 
benefits to ongoing mAb therapy.11 The mAbs have a half-life of 27-30 days, whereas 
rimegepant has a significantly shorter 11 hour half-life. In addition, rimegepant was found to be 
16 times more potent than erenumab at antagonism of CGRP-mediated cyclic adenosine 
monophosphate (cAMP) signaling in whole-cell assays, so combination therapy may provide an 
additive benefit in blocking the intracellular cascades leading to vasodilatory effects.12 
Additional studies to verify and uncover the sources for the efficacy of combination therapy are 
warranted. 
The second case series reports on 13 subjects with migraine on a stable dose of a CGRP 
mAb who treated acute attacks with rimegepant. The goal was to assess the rate of on-treatment 
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adverse events. No subjects had serious adverse events, adverse events leading to 
discontinuation, or aminotransferase levels >3x the upper limit of normal.13 Given that the 
combination treatment was well tolerated, the authors called for studies of larger patient 
populations to confirm their findings. This study is limited by its open label design and short 
duration of follow up. In regards to mechanism, the study proposes a theory that the CGRP 
receptor occupancy may decrease between injections of a CGRP mAb, which would lead to 
increases in unbound CGRP levels in the plasma.13 Prior modeling studies have indicated that 
during the month following an injection of a ligand targeted mAb (i.e. galcanezumab, 
fremanezumab, eptinezumab), CGRP plasma levels first drop then return to baseline with up to 
36% to 55% of CGRP unbound with the potential to induce breakthrough attacks by binding to 
their receptor.14 Therefore, rimegepant acting on the receptor itself is likely to provide a targeted 
benefit in aborting these acute attacks. In addition, with a progressive rise in CGRP plasma 
levels throughout the month, this suggests there may be an optimal period during which patients 
would benefit, or conversely, a period where potent blockade poses risk associated with 
excessive blockade of CGRP activity. 
2.4 Review of Rimegepant Efficacy Trials 
Although there are no published RCTs investigating concomitant use of CGRP mAbs and 
rimegepant, multiple studies have examined the relationship between rimegepant and freedom 
from pain at 2 hours, as well as other secondary variables to be analyzed in this proposed trial. 
Two similar randomized, double-blind, placebo-controlled, multi-center phase 3 trials, both with 
over 1,000 subjects, demonstrated that a single 75 mg dose of rimegepant was more effective 
than placebo in freedom from pain at 2 hours —21% versus (vs) 11%, Risk Difference (RD) 10.4 
(95% Confidence Interval (CI) 6.5 to 14.2),  p<0·000115 and 19.6% vs 12.0%, RD 7.6 (95% CI 
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3.3 to 11.9), p<0.00116 —and freedom from the most bothersome symptom (MBS) at 2 hours—
35% vs 27%, RD 8.3 (95% CI 3.4 to 13.2), p=0·000915 and 37.6% vs 25.2%, RD 12.4 (95% CI 
6.9 to 17.9), p<0.00116. There was also a positive response shown at 60 minutes post-dose and 
continuing through 48 hours post-dose suggesting rimegepant’s duration of effect might provide 
advantages over triptans and other gepants.15 In addition, one randomized dose-ranging trial of 
rimegepant compared the intervention to placebo with sumatriptan as an active comparator. 
Rimegepant was found to be superior to placebo were the percentage of subjects who were pain 
free at 2 hours were at doses of 75 mg (31.4%, p=0.002), 150 mg (32.9%, p<0.001), and 300 mg 
(29.7%, p=0.002), compared to placebo with 15.3% and rates of adverse events, although mild in 
intensity, were dose dependent.17 This trial was not designed with statistical power to allow 
comparison of the sumatriptan arm against the rimegepant arm, however the trial did 
demonstrate that sumatriptan was also more effective than placebo with respect to the primary 
endpoint of pain freedom (35%, p<0.001).17 Furthermore, although the patient numbers were 
small, 2% of subjects reported events of chest discomfort, chest pain, and jaw pain all within the 
sumatriptan-treated arm. Even the highest dose of rimegepant administered in the trial (600 mg) 
did not incur similar events.17 A meta-analysis of 3,827 pooled subjects from four RCTs, 
including the three discussed above, supported that 75 mg rimegepant led to significant freedom 
from pain (20.6% vs 12.5% for rimegepant vs placebo, Risk Ratio (RR) 1.70, 95% CI 1.39 to 
2.08, p<0.001), pain relief (58.6% vs 44.6%, RR 1.34, 95% CI 1.25 to 1.44, p<0.001), and 
freedom from MBS (36.0% vs 25.1%, RR 1.44, 95% CI 1.23 to 1.68, p<0.001) at 2 hours post-
dose compared with placebo.18 Much of the methodology included in this proposal is adopted 




2.5 Review of Methodology 
Study Design 
In the empiric trials presented above, rimegepant is compared to placebo and subjects 
treated a single migraine attack with the active intervention.15,16 Challenges to this study design 
emerge on two main accounts with the first being the lack of an active comparator, and the 
second being the treatment of only a single attack. 
 These studies have been critiqued for failing to justify the comparison of rimegepant to 
placebo, as opposed to an active comparator, when other therapeutic interventions exist for 
migraine. The ethics of the design have been called into question as half of subjects were 
allowed to experience severe pain, often resulting in an inability to work or perform typical daily 
activities. However, in the setting of a single migraine attack study, long-term harm from a non-
active comparator is unlikely and informed consent can be used to justify the use of a placebo.19 
To improve upon ethical standards, this proposed study design includes offering rescue therapies 
to all participants to be used 2 hours after administering rimegepant or placebo if needed. Also, if 
at any point unbearable pain is experienced, the rescue medication may be self-administered and 
will be documented as an intervention failure. Although a non-inferiority design could be used to 
compare a new medication with established treatment, it’s difficult to put forth any single 
abortive treatment as standard of care. Even the widely used triptans do not lead to response in 
33% of patients.16 Another argument is that demonstrating superiority to placebo rather than an 
active comparator is more likely to result in positive findings for the medication, but have less of 
an impact on therapy choices in clinical practice.19 One RCT compared rimegepant to placebo, 
but included sumatriptan (100 mg) as an active comparator. Both rimegepant and sumatriptan 
were found to be superior to placebo in freedom from pain at 2 hours, however the trial was not 
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designed with statistical power to allow head to head comparison of the sumatriptan arm against 
the rimegepant treatment arms.17 Therefore the addition of sumatriptan as an active comparator 
without designing the trial with the goal of demonstrating non-inferiority is unlikely to add much 
strength to the study results when the primary goal is to compare those on or not on a mAb.  
 The single-attack study design has been criticized for the lack of generalizability that can 
be applied to the efficacy and safety outcomes of the studies because consistency of response to 
the medication cannot be assessed.20 The authors do call for future trials to establish the benefits 
of rimegepant across multiple attacks, however in defense of this design, studies of single 
migraine attacks are the global standard for establishing efficacy of acute treatments of migraine 
and for regulatory approval in the US. Multiple-attack studies can be affected by un-blinding 
(where patients learn to distinguish active drug from placebo) and carryover effects, so the first 
attack is used to define primary efficacy endpoints.20 In order to maintain the randomization and 
blinding of a single-attack study but also provide an opportunity to extend results beyond that of 
primary efficacy, the multi-phase trial design is proposed to subvert these critiques. For more 
detailed information on the proposed study design please refer to 3.1 Study Design. 
Study Population 
The study population from which subjects are to be recruited consists of adults with 
migraine who have been on a stable dose of a CGRP mAb (erenumab, galcanezumab, 
fremanezumab, or eptinezumab) for at least 3 months. The CGRP mAbs are administered 
monthly (or quarterly for fremanezumab and eptinezumab), none are available generically, and 
therefore the medications incur costs to patients, private insurance companies, and government 
funded programs. Public paid claims data was used to estimate the number of people in the U.S. 
who are on a CGRP mAb for migraine prevention. The most recent data available shows that in 
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2019, Medicaid and Medicare Part D spending totaled $48,010,499 and $119,459,268, 
respectively, to pay for Aimovig (erenumab-aooe) alone.21,22 Using this data, it can be estimated 
that 7,208 and 16,828 patients were covered by Medicaid and Medicare, respectively, for a year 
supply of the medication in 2019. With inclusion of those covered for galcanezumab and 
fremanezumab, the estimated number of Medicaid and Medicare patients on a CGRP mAb in 
2019 totals 42,279 patients. Please refer to APPENDIX A: Study Population Approximation, for 
calculations. This is likely a gross underestimation of the number of patients on a mAb currently, 
as eptinezumab was not FDA approved until 2020 and the remaining three mAbs were only 
approved in 2018.23 For example, with erenumab, there was a 2% increase in spending from 
2018 to 2019 for both Medicaid and Medicare, and likely continued to increase by 2021.21 Also, 
an even higher growth rate may be expected from 2019 to 2020 in the setting of the Covid-19 
pandemic during which a number of patients were transitioned from botulinum toxin therapy to a 
mAb for migraine prevention as office visits were made limited. 
It is necessary to realize this estimate does not include what is expected to make up the 
majority of the study population– the number of patients who obtain a CGRP mAb through 
private insurance or a payment assistance program funded by the pharmaceutical company. It is 
estimated that 75% of Aimovig prescriptions cost patients $5 or less per month including those 
where the Aimovig Ally™ Access Card was used (the card is available to those with private 
insurance). The remaining 25% of Aimovig prescriptions cost privately insured patients an 
average of $82 per month.24 Although difficult to obtain data to estimate the number of patients 
enrolled in the payment assistance program or covered by private insurance, the majority of 
patients’ relatively low copay is supportive that cost would be less of a barrier for most US 
citizens to be able to access the medication. Based on these data and the calculated estimates 
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obtained from it, recruiting patients from the study population in this multi-center US based 
study to satisfy the desired sample size is both realistic and attainable. For more detailed 
information on recruitment, please refer to 3.4 Recruitment. 
Selection Criteria 
The selection criteria for subjects to participate in this trial is similar to the rimegepant vs 
placebo RCTs and based on International Headache Society (IHS) Guidelines for controlled 
trials of acute treatment of migraine attacks in adults. 15-17,25 A complete list of inclusion and 
exclusion criteria can be referred to in 3.2 Study Population and Sampling. 
One of the most notable exclusion criteria is for subjects with a history with current 
evidence of uncontrolled, unstable, or recently diagnosed cardiovascular disease, cerebrovascular 
disease, or uncontrolled hypertension. Clinical trials of the mAbs showed cardiovascular safety 
issues deemed unrelated to treatment.2 Although no adverse cardiac effects have been observed 
thus far in rimegepant vs placebo studies or in the concomitant CGRP mAb and rimegepant case 
series, this exclusion criteria is recommended for the purpose of safety.10,13,15,16 CGRP is 
important for maintenance of cardiovascular homeostasis and could possibly prevent cerebral or 
cardiac ischemia with its induction of vasodilation.2 The limited data surrounding CGRP 
blockade by two medications and lack of long-term safety studies make it critical to consider 
those with preexisting risk factors in order to prevent a cardiovascular-related adverse event.9 
Therefore this population should not be included in this particular study with the knowledge that 
as results from long-term safety studies of rimegepant emerge, it may support including 
cardiovascular patients in future studies.  
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Efficacy Parameters and Outcomes 
The primary outcome of freedom from pain at 2 hours and secondary outcomes including 
freedom from most bothersome symptom (MBS) at 2 hours, time to freedom from pain etc. are 
all seen in the empirical trials of rimegepant vs placebo discussed earlier.15-17 This is fairly 
standard in that acute migraine treatment trials which are well designed in accordance with IHS 
Guidelines and all have the same, if not similar, efficacy endpoints.25 Where there is variation in 
the proposed trial is the addition of the Migraine Specific Quality of Life Questionnaire (MSQ) 
to assess the effect of migraine on daily functioning. The MSQ is a psychometrically valid tool 
that can be used to reliably measure the impact of migraine among both episodic and chronic 
migraine patients. It was found that MSQ change scores were higher in magnitude in groups 
experiencing greater decline in headache frequency, e.g. a >50% improvement in headache 
frequency correlated with a 23.3 mean change in MSQ score (Standard Deviation (SD) 24.0), 30-
50% improvement correlated with a 12.6 mean change in MSQ score (SD 20.1), and a <30% 
improvement in headache frequency correlated with a 3.0 mean change in MSQ score (SD 14.0) 
yielding a p-value of <0.001 for between-category comparisons.26 Although the proposed trial is 
focused on acute outcomes from rimegepant intervention, improvements in management of 
migraine attacks also has broadened impacts on patients’ functioning and overall quality of life. 
If an acute attack is treated more rapidly and with sustained relief, there will be fewer impacts on 
daily life activities. Therefore, the inclusion of this questionnaire adds strength to the existing 
framework of acute migraine treatment trials. 
 Outcomes for the proposed study are attained from subjects’ self-reporting through the 
use of an electronic Patient Reported Outcomes diary (ePRO diary). This is recommended by 
IHS guidelines as an ePRO diary has time-stamp capabilities and also provides an opportunity 
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for adverse events (AEs) to be communicated with the research team in real time. Simplicity of 
the electronic report form is of the utmost importance, as the quality of collected data decreases 
as the quantity increases.25 The goal is for the form to be as easy as possible for subjects to fill 
out during attacks. In prior rimegepant studies, an ePRO Diary was exclusively used for outcome 
reporting.15,16 However, to remain inclusive of those subjects with significant photophobia as 
part of their migraine symptom profile, one may opt for a near-identical paper option so as not to 
preclude their ability to report outcomes. Also, during the Run-in Period, all subjects will 
practice documenting their symptoms in the diary with acute attacks. Those who are unable to 
consistently document, will be excluded from further participation in the trial. 
 Additionally, participant-reported outcomes come with concerns of report bias. The 
subjective interpretation of symptoms and pain severity level will inevitably vary from person to 
person. However, with the simple, standardized numerical pain scale (0 = No pain, 1 = Mild 
pain, 2 = Moderate pain, or 3 = Severe pain) recommended by IHS guidelines, there is less room 
for major variations in subject reporting.25 Furthermore, the open-label secondary phase of the 
proposed study will allow for within-subject comparisons, wherein subjective pain ratings will 
be more consistent across multiple attacks for each subject. Lastly, the primary endpoint of 
freedom from pain is more easily defined than a reduction in pain which involves more 
subjective judgement (i.e. the difference between no pain and any degree of pain is binary, 
whereas the difference between mild and moderate or moderate and severe pain is not as 




2.6 Review of Possible Confounding Variables 
Demographics Variables 
One demographics variable which may exert an effect on the outcome is sex. Migraine is 
up to 3 times more prevalent in women than in men, and women with migraine have more 
frequent and severe headache attacks.2 In rodent models, the application of CGRP to the dura 
mater induce behavioral responses consistent with headache only in female rats. Females show 
significantly lower facial withdrawal thresholds at 3, 5, and 24 hours after injection (p < 
0.0001).27 This suggests the CGRP receptor itself is implicated in the higher prevalence of 
migraine in women. The difference may be related to hormonal fluctuations e.g. in estrogen and 
progesterone, potentially affecting CGRP signaling.2 Although gepants and mAbs have both 
been shown as safe and exert an effect in both male and female patients, existing studies lack the 
statistical power to assess a potential sex difference in efficacy.2 For the proposed study, a 
female to male subject ratio that approximates the migraine population will be sought, serving to 
make the findings from this study generalizable to migraine. 
Another factor which raised concern for confounding in previous rimegepant trials is 
obesity. Women with obesity formed the majority of the study population. This was criticized for 
the potential effect it may have on pharmacokinetics, however body-mass index (BMI) was not 
found to predict response to rimegepant.15,18,20 Also, as discussed above, migraine is 
predominantly a disease of women, and 43% of adults aged 40-59 years are obese.20 For this 
study, the research pharmacy will attempt to recruit from a more diversified population in terms 
of sex and weight, especially given the multi-center setting, however it is understood that these 
imbalances may only account for the natural differences in disease prevalence and thus far have 




In prior rimegepant vs placebo studies, subjects were allowed to have been on a stable 
dose of a preventive medication for at least 3 months prior to the trial. The results were stratified 
dichotomously, with participants answering if they were on a preventive (yes/no), however the 
different types of preventive medications the subjects were on are not described.15,16 This could 
have confounded outcomes in that some prophylactic medications can reduce severity of acute 
migraine attacks more than others.28 This may impact the level of ease with which the migraine 
is successfully treated. In the proposed study, subjects are intentionally on mAb preventives (and 
allowed to currently be on one additional non-mAb preventive), and controls are allowed to be 
on a stable dose of no more than two non-mAb prophylactic medications. Given that 87% of 
those with episodic migraine take no preventive medications, it will be attempted to balance the 
number of subjects and controls currently on other preventive treatments in order to minimize the 
effect of this confounding variable.28 However, given the inclusion criteria requiring 2-8 
migraine attacks per month in the 3 months prior to screening and maintained during the Run-in 
Period, as long as the subject is meeting this migraine burden, it is less likely the different 
preventives will pose an issue of confounding. This also allows the control subjects to be more 
representative of the episodic migraine population at large and improve generalizability of this 
study’s results. 
Migraine Triggers 
In terms of the migraines themselves, subjects may have their own identifiable triggers 
which tend to induce a migraine, and this is an element which would be difficult to control for in 
the proposed study. Common triggers involve disturbances in sleep, exercise, diet, and stress, 
with successful management mitigating migraine burden.29 Although subjects will be encouraged 
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to minimize major changes to their routine and medications while optimizing healthy habits in 
regards to those four pillars, variation will inevitably exist throughout the study. This may not 
only influence how often a particular subject has a migraine, but also how hard it may be to treat. 
Pharmacologic treatment may not impart relief without simultaneous management of the 
particular trigger (i.e. a subject who is sleep deprived, would likely require sleep in addition 
medication in order to relieve their migraine).29 Throughout the Secondary Phase of the study, 
patterns may be recognized within subjects’ reported symptoms and outcomes as they treat 
multiple attacks with rimegepant. This could reveal to the researcher specific underlying triggers 
influencing the results. However, it is realized that the differences among subjects in the 
prophylaxis and management of their triggers, may confound the outcomes in almost all 
migraine studies. 
Rimegepant Formulation 
With regards to the active intervention, rimegepant is formulated as an oral disintegrating 
tablet (ODT) which has been recognized for its fast absorption and time to peak plasma 
concentration.15 This must be considered as it has been associated with relatively rapid onset of 
relief seen in subjects. Other migraine agents have also prioritized an ODT formulation given 
that many patients have associated nausea with acute attacks. This is done with the intention of 
increasing speed of absorption and onset of effect while mitigating the effects of migraine on the 
gastrointestinal system.30 In the proposed study, the placebo tablet will be designed with the 
same taste, shape, and disintegrating properties as the active intervention. Also, pain outcomes 
are to be tracked for 24 hours after self-administering the intervention so that not only the rapid 




This review of the literature demonstrates the novelty of concomitant use of rimegepant 
with CGRP mAb therapy and the necessity for a RCT investigating their combined efficacy and 
safety. The studies that investigate the CGRP pathway and potential mechanisms of rimegepant 
in the context of the mechanisms of mAbs aid the understanding of how their combined use may 
improve pain outcomes. These studies also lead researchers to consider the potential for adverse 
events to arise. This information is critical in the design of the proposed study such that it is not 
only feasible but also safe. Next, the case series reviewed in this chapter reveal promising results 
for concomitant use of the medications, however they lack the number of subjects, blinding, and 
randomization to demonstrate efficacy, so each of these areas are addressed in the proposed 
methods. Also, previous RCTs demonstrating the safety and efficacy of rimegepant are discussed 
in order to highlight portions of the methodology that are to be either replicated or improved 
upon to conduct an effective study while reducing bias and confounding where possible. The 
review identifies the gap in this area of research and utilizes what information is available to fill 
that gap with a RCT that will generate data for the benefit of both providers and the patients for 
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CHAPTER 3: STUDY METHODS 
3.1 Study Design 
This multi-center, biphasic trial will evaluate the safety and efficacy of rimegepant 75 mg 
ODT for acute migraine treatment with concomitant anti-CGRP or anti-CGRP receptor mAb for 
migraine prevention. The Primary Phase will consist of a randomized, double-blind, placebo-
controlled single-attack study, and the Secondary Phase will be a 2 month open label multi-
attack study. 
3.2 Study Population and Sampling 
The source population from which the study and control populations will be acquired 
consists of adults ages 18-65 years old with at least a 1 year history of migraine with or without 
aura. The study population (herein interchangeably referred to as the mAb group) will have been 
treated with a stable dose of an injectable anti-CGRP or anti-CGRP receptor monoclonal 
antibody: erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), or 
eptinezumab (Vyepti) for at least 3 months prior to screening. The control population (herein 
referred to as the control group) will include those who have never used anti-CGRP or anti-
CGRP receptor mAbs. The complete inclusion and exclusion criteria, which have been partially 
adopted from a previous clinical trial investigation of rimegepant, can be seen below.1  
Inclusion Criteria:  
1. Adults ages 18-65 years old with at least a 1-year history of migraine with or without 
aura consistent with a diagnosis according to the International Classification of Headache 
Disorders, 3rd edition, (ICHD-3, 2018) 
2. Age at onset of migraine is <50 years old. 
3. History of 2-8 migraine attacks per month in the 3 months prior to the Screening Visit 
and maintains this requirement during the Run-in Period. 
4. Less than 15 days with headache (migraine or non-migraine) per month in the 3 months 
prior to the Screening Visit and maintains this requirement during the Run-in Period. 
5. Study subjects: Appropriately administered stable dose of erenumab, galcanezumab, 
fremanezumab, or eptinezumab for at least 3 months prior to study. 
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a) Use of other migraine preventives is permitted. Study subjects may be on a stable 
dose of no more than one prophylactic agent, as determined by the investigator, 
for at least 3 months prior to the study. 
6. Control subjects: naïve to an anti-CGRP or anti-CGRP receptor monoclonal antibody. 
a) Use of other migraine preventives is permitted. Control subjects may be on a 
stable dose of no more than two prophylactic agents, as determined by the 
investigator, for at least 3 months prior to study. 
7. All subjects should maintain their preventive regimen and not alter it during the study. 
8. Patients with contraindications to use of triptans may be included provided they meet all 
other study entry criteria. 
9. Have a sitting pulse rate ≥ 45 beats per minute (bpm) and ≤ 100 bpm during the vital sign 
assessment at the Screening Visit. Clinical site may perform a maximum of 2 repeats of 
vital sign measurements if the initial measurement is out of range. 
10. Women of childbearing potential must be using two acceptable methods of contraception 
to avoid pregnancy throughout the study in such a manner that the risk of inducing 
pregnancy is minimized for the duration of the clinical study and up to 8 weeks after the 
study. 
a) Must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L 
or equivalent units of HCG) 
b) Women must not be breastfeeding 
 
Exclusion Criteria: 
1. Current use of a gepant for acute migraine treatment 
2. Previously participated in an investigational study of a gepant 
3. Difficulty distinguishing migraine headache from tension-type or other headache types 
4. Has a history of menstrual migraine, migraine aura with diplopia or impairment of level 
of consciousness, hemiplegic migraine, retinal migraine, or medication overuse headache 
as defined by ICHD-3 
5. Has a current diagnosis of new persistent daily headache, trigeminal autonomic 
cephalalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 
6. Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to 
screening 
7. Participation in any other clinical investigation using an experimental drug or other 
therapy (e.g. neuromodulatory devices) within 30 days prior to study intervention 
administration 
8. Participation in a blood or plasma donation program within 60 or 30 days, respectively, 
prior to study intervention administration. 
9. Positive drug screen for drugs of abuse that in the investigator’s judgment is medically 
significant, in that it would impact the safety of the patient or the interpretation of the 
study results. In addition:  
a) Detectable levels of cocaine, amphetamine, barbiturates and phencyclidine (PCP) 
in the drug screen are exclusionary. Patients who are positive for amphetamines 
or barbiturates on the urine drug screen may have their urine samples evaluated 
for further analysis at the investigator’s discretion to rule out a false positive 




b) Detectable levels of marijuana in the initial drug screen are not exclusionary, 
however subjects must have a negative test before initiating the Run-in Period and 
remain negative throughout the study in order to participate. 
10. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months 
or patients who have met DSM-V criteria for any significant substance use disorder 
within the past 12 months from the date of the Screening Visit 
11. Patient history of HIV disease 
12. Patient history of Polycystic Ovarian Syndrome (PCOS) 
13. Patient history with current evidence of uncontrolled, unstable or recently diagnosed 
obstructive sleep apnea (OSA), cardiovascular disease, such as ischemic heart disease, 
coronary artery vasospasm, and cerebral ischemia. Patients with Myocardial Infarction 
(MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), 
cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to 
screening. 
14. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however 
patients can be included who have stable hypertension and/or diabetes for 3 months prior 
to being enrolled) 
15. Patient has a current diagnosis of major depression, other pain syndromes, psychiatric 
conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other 
than migraine) that, in the investigator’s opinion, might interfere with study assessments 
16. Patient has a history of gastric, or small intestinal surgery, or has a disease that causes 
malabsorption 
17. Has a history or current evidence of any significant and/or unstable medical conditions 
(e.g. congenital heart disease or arrhythmia, known or suspected infection, cervical 
disease, End Stage Renal Disease, hepatitis B or C, or cancer) that in the investigator’s 
opinion, might interfere with study assessments or place the patient at higher risk of a 
significant adverse event. 
18. ECG and Laboratory Test Findings 
a) Estimated glomerular filtration rate (eGFR) according to the re-expressed 
abbreviated (four-variable) Modification of Diet in Renal Disease (MDRD) Study 
equation ≤ 40 ml/min/1.73m2 
b) Corrected QT interval > 470 msec (QTc by method of Frederica), during the 
Screening/Baseline Phase 
c) Left Bundle Branch block  
d) Right Bundle Branch Block with a QRS duration ≥ 150 msec. 
e) Intraventricular Conduction Defect with a QRS duration ≥ 150 msec. 
f) Serum bilirubin (Total, Direct and Indirect) > 1 x ULN (Only abnormal values of 
between 1-1.5x ULN may be repeated once for confirmation during the screening 
period.) 
g) AST (SGOT) or ALT (SGPT) > 1 x ULN (Only abnormal values of between 1-
1.5x ULN may be repeated once for confirmation during the screening period.) 
h) Neutrophil count ≤ 1000/µL (or equivalent). 
19. Prohibited concomitant medication prior to randomization and during the course of the 
study or as specified. 
a) St. John’s Wort should not be taken 14 days prior to randomization and 
throughout the study. 
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b) History of use of ergotamine medications on greater than/equal 10 days per month 
on a regular basis for greater than/equal 3 months 
c) History of non-narcotic analgesic intake on greater than/equal 15 days per month 
for greater than/equal 3 months 
d) Use of narcotic medication, such as barbiturates, heroin, opium in the form of 
morphine and codeine, oxycodone and hydrocodone for at least 2 days prior to 
randomization. 
e) Use of acetaminophen or acetaminophen containing products after randomization 
is prohibited, except as rescue medication as described in protocol. Any use of 
acetaminophen or acetaminophen containing products during screening must be 
stopped at least 2 days prior to randomization. 
 
3.3 Subject Protection and Confidentiality 
Written informed consent must be obtained from the patient in accordance with 
requirements of the study center’s institutional review board (IRB) or ethics committee, prior to 
the initiation of any protocol-required procedures. The consent forms will be available in 
English, Spanish, and translated into additional languages as necessary. The consent form 
contains a study description, explanation of the purpose of the research, duration of participation, 
potential risks and benefits, methods of protecting confidentiality, a clear statement that 
participants may withdraw at any time, and a statement that the investigators reserve the right to 
terminate a subject’s involvement at any time. All subjects will be informed if significant new 
findings develop during the course of the study that may affect whether they are willing to 
continue participation. The consent form will be explained to each subject individually and 
privately by research personnel and participants will be given the opportunity to ask questions 
and discuss concerns prior to issuing consent (APPENDIX B: Sample Informed Consent Form). 
At the time of enrollment, immediately after written informed consent is obtained and 
before performing any study-related procedures, each subject will be assigned a unique 
sequential 4-digit subject number beginning with 0001, 0002, 0003, etc. for identification 
throughout the study. This subject number must not be reused for any other participant in the 
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study. Each subject will be provided with an electronic Patient Reported Outcomes (ePRO) 
Diary on a secure handheld electronic device to ensure stored data is only shared with the 
research team throughout the study. The device will be returned at the trial’s conclusion for 
proper de-identification and disposal of subject data. The method of blinding investigators and 
subjects as well as the collection and storage of health information obtained both in clinic and 
electronically will comply with all relevant privacy standards and regulations as written in the 
Health Insurance Portability and Accountability Act (HIPAA). All study personnel will complete 
HIPAA training. 
The study protocol is written in accordance with the most recently updated Guidelines of the 
International Headache Society (IHS) for controlled trials of acute treatment of migraine attacks 
in adults: fourth edition.2 This ensures the protection of subjects as the guidelines were created to 
allow for a safe, standardized, and evidence-based approach to the conduct of randomized 
controlled trials within this specific discipline. 
3.4 Recruitment 
Subjects will be recruited through outpatient offices, online advertising, and word of 
mouth. At sites involved with the study, healthcare providers will provide a brochure and refer 
potential participants to contact the research coordinator, who will arrange for a phone screening 
based on the inclusion and exclusion criteria (see APPENDIX C: Phone Screening Questions). 
Eligible candidates will be brought in for in-person screening and if they continue to meet the 
remaining criteria, they will be given the opportunity to enroll in the study and provide written 
informed consent. Participants will be continuously enrolled until reaching the target sample 
size, and participants will begin the study as recruitment ensues. 
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3.5 Timeline and Resources 
Based on previous studies involving similar populations with more subjects, the 
enrollment period is expected to span approximately 12 months to achieve the target sample size 
including both subjects on a CGRP mAb and control subjects who have never used a CGRP 
mAb.1 For each enrolled subject, a Run-in Period of 4 weeks, the Primary Phase of 1 to 8 weeks, 
and the Secondary Phase of 8 weeks, totals a 13-20 week time commitment. Accounting for 
enrollment and the length of data collection, study completion will be within 2 years. 
 Study materials and personnel required to carry out the study include: 
- Co-primary investigators, 2 research assistants 
- Site coordinator, 1 research assistant, and 1 LPN or RN (for each site) 
- Research pharmacy responsible for balancing demographics variables during 
recruitment, use of randomization software, and blinded allocation of intervention in 
blister packs 
- Informational brochure for recruitment (see APPENDIX D: Recruitment Brochure) 
- Electronic Patient Reported Outcomes ePRO Diary, a secure hand held electronic 
device for each subject with instructions for use (or alternative paper version of 
reported outcomes diary) 
- Laboratory kits and laboratory manual 
o Safety laboratory, plasma, serum, instructions for all specimens collected will 
be provided by a designated central laboratory. 
- ECG Machine, electronic blood pressure monitor, thermometer, scale 
o Equipment, supplies, instructions, and training materials will be supplied by a 
centralized medical supplies vendor. 
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- Migraine-Specific Quality of Life Questionnaire (MSQ) electronic or paper forms 
(see APPENDIX E: Migraine Specific Quality of Life Questionnaire (MSQ)) 
- Serious Adverse Event (SAE) case report forms 
- Investigator brochure for information on rimegepant 
Biohaven Pharmaceuticals, Inc. will sponsor the study. The company will provide rimegepant 75 
mg ODT and blinded placebo tablets, as well as additional funding support. A fully executed 
Data Use Agreement (DUA) is in place between Biohaven and the primary study site. 
3.6 Study Protocol and Intervention 
Run-in Period 
Subjects who have been screened and consented will enter a Run-in Period for 4 weeks 
during which migraine frequency will be monitored with a requirement of 2-8 migraine attacks 
during the period in order to continue on in the study. They will also have baseline safety 
measurements assessed: Physical examination, vital signs/ physical measurements, clinical safety 
laboratory testing, ECG, assessment of migraine history (signs and symptoms), and pregnancy 
test (See APPENDIX F: Safety Assessments). To document each migraine attack during the 
Run-in Period, the participant will use a provided electronic Patient Reported Outcomes (ePRO) 
Diary via secure handheld electronic device with time stamping capability which will prompt 
documentation of pain, symptoms, and adverse events in the same way it will during the study. 
Subjects may use their personal standard of care abortive treatments for each attack. This will 
allow the participants to adjust to using the ePRO Diary and assess procedural compliance. Non-
compliant subjects and those who do not meet the required number of migraine attacks will be 
excluded from further participation in the study. Those who will go on to randomization and 
allocation will be administered a baseline Migraine-Specific Quality of Life Questionnaire 
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(MSQ). The MSQ is a self-administered, migraine-specific, 14-item instrument assessment of 
quality of life that was developed to assess the effect of migraine on daily functioning (see 
APPENDIX E: Migraine Specific Quality of Life Questionnaire (MSQ)).  
Intervention 
The intervention is single dose (75 mg) oral disintegrating rimegepant (Nurtec-ODT 
[Biohaven Pharmaceuticals, New Haven, CT] for abortive treatment of migraine attacks of 
moderate or severe intensity. The placebo is an oral disintegrating tablet identical in appearance, 
taste, and dissolution quality as the rimegepant tablet. Subjects will be educated on how to 
properly allow the tablet to dissolve orally and no more than one tablet may be administered 
every 24 hours. 
Randomization and Assignment of Intervention 
For the Primary Phase of the study, subjects in both the mAb group and the control group 
will be randomly assigned by a computer program in a 1:1 ratio to rimegepant or placebo for 
treatment of a single migraine attack of moderate or severe pain intensity. Both investigators and 
participants will be blinded as to their assignments. A blister pack containing a single tablet 
(rimegepant or placebo) will be provided to each subject by the research pharmacy. This phase 
extends for a maximum of 8 weeks, and those who do not have a migraine attack during that 
period will be excluded from further participation in the study. Those who treat their single 
attack prior to the 8 week mark may advance to the Secondary Phase. 
 For the Secondary Phase of the study, beginning after the subject treats their first attack, 
all subjects in both groups will receive rimegepant to treat multiple migraine attacks of moderate 
or severe pain intensity over an 8 week period. A blister pack containing twelve 75 mg 
rimegepant tablets will be provided initially. Some subjects may have more frequent attacks than 
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others and require more medication, so they will be instructed to notify the research pharmacy 
when they have four tablets remaining and an additional allotment of four tablets can be shipped 
to them, with a maximal allotment of 16 tablets total for the 8 week period (accounting for a 
maximum of 8 migraine attacks per month). 
Table 1. Study Protocol Timeline 
Group Run-in Period 
4 weeks 
Primary Phase (Blinded) 
1 migraine attack 
Secondary Phase (Open Label) 
8 weeks 
Control  Rimegepant Rimegepant 
  Placebo Rimegepant 
Monoclonal Antibody  Rimegepant Rimegepant 
  Placebo Rimegepant 
 
3.7 Data Collection 
At the time of a migraine attack, subjects will begin documentation in their ePRO Diary. 
The first question will be to rate their pain on a numerical rating scale from 0-3, where 0 is no 
pain, 1 is mild pain, 2 is moderate pain, and 3 is severe pain. If a subject rates their pain a 2 or 3 
(moderate or severe) one will be asked additional questions via the ePRO Diary regarding 
specific symptoms (see Table 2) before being prompted to self-administer the allocated tablet to 
treat the attack. If a subject rates their pain a 1 (mild), one will be asked to refrain from self-
administering the allocated treatment and only if the pain increases to a 2 or 3 will the patient 
restart the documentation process in the ePRO Diary and proceed with treatment. If a subject 
takes their own medication (i.e. ibuprofen, acetaminophen etc.) at the time where pain was a 
level 1 and has now increased to a 2 or 3, they are not to administer the allocated treatment and 
this migraine attack cannot be included in the study. 
 Once the subject has self-administered the allocated treatment, the ePRO Diary will 
prompt to reevaluate symptoms and pain at 30 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 
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4 hours, 8 hours, 12 hours, 24 hours (see Table 2). There will be an option to report adverse 
events at any time during the study (and within 30 days of discontinuation of the trial). This will 
include documentation of event severity (mild, moderate, severe), time of onset (ePRO Diary 
will automatically timestamp entry), and time of resolution. In addition, subjects will be 
instructed to directly contact study personnel for any adverse event with potentially serious 
implications (e.g., chest pain, uncontrolled vomiting) within 24 hours. Subjects will be provided 
a 24 / 7 contact telephone number to call for such events. All adverse events deemed to be 
serious, as determined by the study investigator, will be followed to resolution or stabilization. 
All serious adverse events (SAEs) will be reported to the IRB within 72 hours (see APPENDIX 
F: Safety Assessments). 
 To maintain ethical standards, subjects who do not experience freedom from pain 2 hours 
after administering the allocated treatment during either phase of the trial will be allowed to use 
an approved rescue medication. Permissible rescue medications are aspirin, ibuprofen, naproxen, 
other nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen (up to 1000 mg/day), 
antiemetics (e.g. metoclopramide or promethazine), triptans, or baclofen. Other rescue 
medications may be deemed acceptable by the co-primary investigators on a case by case basis at 
the start of the trial. If a subject experiences unbearable pain prior to 2 hours and uses a rescue 
medication, this will be considered a treatment failure. If needed, after 48 hours of administering 
the study medication, patients may take their standard of care abortive medication(s) (including 
triptans if not contraindicated). Use of a rescue medication must be documented in the ePRO 
Diary at the time of administration. 
 After a subject has treated their first migraine attack with the allocated intervention 
(rimegepant or placebo), one will return to clinic for safety assessment evaluation within the 
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week of treatment (see APPENDIX F: Safety Assessments). If safety is assured, subjects will 
move on to the Secondary Phase and be given their blister pack of twelve 75 mg rimegepant 
tablets. Once again, subjects are only to treat migraine attacks of moderate or severe pain with 
one tablet and will document in their ePRO Diary as they did during the first attack with each 
subsequent attack. For the purposes of this study, 48 hours of freedom from moderate (2) or 
severe (3) pain between migraine attacks treated with rimegepant or a rescue medication is 
required.  
 Throughout the Secondary Phase, a period of 8 weeks total, subjects will be monitored 
for adverse events continuously via the ePRO Diary and as described above, all adverse events 
that might potentially be serious must be reported directly to study personnel. Subjects will 
return to clinic for safety endpoint measurements at 2 weeks, 4 weeks, and 8 weeks. A Migraine-
Specific Quality of Life Questionnaire (MSQ) will be administered electronically at 4 weeks and 
8 weeks (see Table 3). Adherence to ePRO Diary reporting and questionnaire response will be 
monitored throughout the study and additional reminders will be delivered electronically to those 
subjects who are consistently failing to report data. 
Table 2. ePRO Diary Prompts and Time Points 
  
 





Primary Phase (Blinded) 
1 migraine attack 
Secondary Phase (Open Label) 
8 weeks 
ePRO Diary w/ attacks w/ attack w/ attacks 
MSQ End of week 4  End of weeks 4 and 8 
Safety 
Endpoints 
Screening (Day -1) After attack End of weeks 2, 4, and 8 (formally); 
potentially serious adverse events 
reported any time 
 
Before intervention 30 minutes 60 minutes 90 minutes 2 hours 3 hours 4 hours 8 hours 12 hours 24 hours
Pain rating (0-3) x x x x x x x x x x
Identify most bothersome symptom x
Phonophobia (0-3) x x
Photophobia (0-3) x x





3.8 Outcome Measures 
The primary outcome is freedom from pain at 2 hours after the intervention dose. 
Freedom from pain will be defined by the presence of no pain (0) in a person who had pain of 
moderate (2) or severe (3) intensity immediately prior to administration of the dose. Incidence 
proportions will be analyzed with a chi-square. A secondary outcome will be time to freedom 
from pain, defined in the same way, and analyzed with a Kaplan-Meier test. Operationalization 
and statistical analysis of all primary and secondary outcomes are shown in Table 4. 
 Several additional secondary outcomes will be measured for all subjects. One secondary 
outcome is freedom from most bothersome symptom (MBS) at 2 hours with the MBS having 
been identified just prior to administration of the dose. Another set of secondary outcomes 
include pain relief at 2 hours and time to pain relief where pain relief is defined as mild (1) or no 
pain (0) in a subject who had pain of moderate (2) or severe (3) intensity just prior to 
administration of the dose. In addition, total migraine freedom at 2 hours which is defined as 
having no pain, nausea, photophobia, and phonophobia at the 2 hour time point will be measured 
in all subjects regardless of their initial endorsement of each individual symptom. Use of a rescue 
medication after 2 hours and use of a rescue medication before 2 hours (treatment failure) are 
also secondary outcomes. Also, MSQ scores will be compared and used as a secondary outcome.  
 The following secondary outcomes will be measured conditionally, depending on the 
responses of the subject in their ePRO Diary. Specific migraine symptoms will be assessed with 
freedom from phonophobia at 2 hours, freedom from photophobia at 2 hours, and freedom from 
nausea at 2 hours. These will be measured in those who marked the symptom as moderate (2) or 
severe (3) prior to dose administration and after 2 hours mark the symptom as absent (0). 
Sustained pain freedom will also be measured in those who had pain freedom at 2 hours, and 
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defined as remaining pain free from 2 to 24 hours after administering treatment without use of a 
rescue medication.  
Table 4. Operationalization and Planned Statistical Analysis of Primary and Secondary Outcomes 
Outcome Operationalization Type of Statistical Analysis 
Freedom from pain at 2 hours Dichotomous Chi-square 
Time to freedom from pain Continuous Kaplan Meier 
Freedom from MBS at 2 hours Dichotomous Chi-square 
Pain relief at 2 hours Dichotomous Chi-square 
Time to pain relief  Continuous Kaplan Meier 
Freedom from phonophobia at 2 
hours 
Dichotomous Chi-square 
Freedom from photophobia at 2 hours Dichotomous Chi-square 
Freedom from nausea at 2 hours Dichotomous Chi-square 
Total migraine freedom at 2 hours Dichotomous Chi-square 
Use of rescue medication after 2 
hours 
Dichotomous Chi-square 
Use of rescue medication before 2 
hours (treatment failure) 
Dichotomous Chi-square 
Sustained pain freedom from 2-24 
hours 
Dichotomous Chi-square 
MSQ Scores Continuous Between group minimally 
important differences 
 
3.9 Sample Size Calculation 
One RCT found that the incidence proportion of freedom from pain at 2 hours was 10.9% of 
those who had taken placebo and 21.2% in those who had taken 75 mg of rimegepant.3 The effect 
size (absolute difference of effect) is 10.3%. With a 2-sided significance level of 0.05 (α), and 80% 
power, a minimum sample size of 420 participants was calculated. This yields a sample of 210 in 
the mAb group and 210 in the control group. The projected minimum sample size will further 
consider the anticipation of drop out and discontinuation during the study. The previously 
mentioned trial had a dropout and discontinuation rate of 7.1%. To account for anticipated loss 
during the study period, a sample size of 450 subjects will be sought: 225 subjects in the mAb group 




Variables to describe the population at baseline will be balanced between the mAb group 
and the control group. This will include age, sex, race, ethnicity, and BMI. This will also include 
migraine type in terms of with aura or without aura. Dichotomous variables will be represented 
with counts and percentages. Continuous variables will be summarized with univariate statistics 
(e.g., n, mean, standard error, median, minimum and maximum). 
 Several populations will be analyzed. Enrolled subjects include those who sign an 
informed consent form and are assigned a subject identification number. Randomized subjects 
are enrolled subjects who receive a randomization treatment assignment during the Primary 
Phase (rimegepant or placebo). Treated subjects are enrolled subjects who receive study therapy 
(rimegepant or placebo). Modified Intent to Treat (mITT) subjects are randomized subjects that 
take any amount of study therapy and provide at least one efficacy measurement. 
 Analysis will be performed with a modified intention-to-treat method. Results will be 
statistically significant if p < 0.05. The primary outcome is freedom from pain at 2 hours, 
analyzed via chi-square statistical test between mAb and control groups. Secondary outcomes, 
both dichotomous and continuous variables, and their appropriate statistical tests for analysis are 
listed in Table 4. 
 Exploratory analysis will be performed within subjects who were randomized to receive 
placebo during the Primary Phase and then subsequently administered rimegepant in the 
Secondary Phase. A McNemar’s test will be used to compare outcomes within the same subject. 
The same test will be used to analyze each subject’s consistency of response to rimegepant over 
the course of the Secondary Phase. Lastly, a stratified analysis will compare the response to 
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CHAPTER 4: CONCLUSION 
4.1 Advantages and Disadvantages 
The primary advantage of the proposed study is well defined in the statement of the problem 
as it fills the gap in the investigation of concomitant use of rimegepant with a CGRP mAb through a 
randomized controlled trial. The proposed methods are valid as they were written in accordance 
with International Headache Society (IHS) guidelines and mirror previous rimegepant vs placebo 
RCTs, however improvements have also been made in the proposed study design. With its unique 
biphasic design, this trial is able to maintain a phase with blinding and randomization to investigate 
a single migraine attack while also meeting ethical guidelines in a separate phase allowing the 
investigation of rimegepant’s effects in the acute treatment of several migraine attacks over time. 
Furthermore, the addition of the Migraine-Specific Quality of Life Questionnaire (MSQ) provides a 
more comprehensive measurement of the medication’s impact on patients’ overall migraine 
management. The study is powered appropriately and the sample size is sufficient in comparison to 
previous rimegepant vs placebo RCTs. Compared to the case series for concomitant rimegepant and 
CGRP mAb, the sample size is significantly larger. Lastly, a strength of this study is its 
generalizability. Although the selection criteria are necessarily strict because rimegepant is still a 
fairly new medication, the recruitment of subjects such that the sample emulates the study 
population at large is highly prioritized. The generalizability is also improved by the multi-attack 
phase of the study, where consistency of response to rimegepant may be analyzed. This may also be 
helpful in its application to studies of other members of the gepant class for treatment of acute 
migraine attacks in the future. 
 A potential disadvantage of this study is the confounding variables it poses which are 
difficult to control for. These include patient specific migraine triggers and environmental changes, 
which are present in any migraine treatment study, and therefore expected to arise in this trial. 
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However, an emphasis to patients about maintaining their routines is all that can be realistically 
achieved to address this variable. Second, variability in the types of preventives the control subjects 
are taking poses a potential confounding variable, however in order to maintain the external validity 
of the study it is necessary to include subjects on preventives for their migraines. Lastly, the 
proposed study does not include an active comparator, with rimegepant being compared to placebo. 
It might be argued that the inclusion of an active comparator (e.g. a triptan) would strengthen the 
clinical implications of the study results, however it is beyond the scope of this trial which is 
primarily focused on comparing the effects and safety of the drug in those taking vs not taking a 
CGRP mAb. Depending on results from this study, the inclusion of an active comparator in similar 
future studies might be warranted. 
4.2 Clinical and Public Health Significance 
The findings from this study have the potential to impact patients and their providers as 
well as lead to public health benefits. Both preventive and abortive treatment of migraine are 
addressed in this trial, which are the two pillars of migraine management. The main objective is 
to determine the efficacy of rimegepant with outcome measures focused on pain and symptom 
freedom in the acute setting, however it is the incorporation of the medication in long-term 
migraine management that expands the impacts of this study. Patients’ quality of life is 
implicated since an improved migraine treatment regimen leads to less time in pain, fewer 
disability work days, and less time spent being treated in a healthcare setting. This also has 
impacts on the healthcare system at large, as the total estimated cost of migraine headache 
amounts to $78 billion per year in the US.1 The estimated mean cost for migraine-related care 
per outpatient visit was $139.88, per Emergency Room (ER) visit was $775.09, and per inpatient 
hospitalization was $7,317.07.2 It is cost saving to both the patient and to the health system when 
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there are fewer visits to the ER and fewer hospitalizations related to migraine care. The proposed 
study’s results may expand evidence based management options which would help patients treat 
their migraine attacks at home, decreasing the need for emergency visits and inpatient stays.  
Given the increasing use of mAbs for preventive therapy, understanding the efficacy and 
safety of rimegepant in patients taking such preventives is an important consideration. This study 
will provide data helping to elucidate where rimegepant best fits in migraine management and 
for which subset of patients a benefit is likely to be achieved. With the potential to improve the 
lives of patients, providers will be able to refer to data from a randomized controlled trial before 
prescribing their patients concomitant rimegepant and CGRP mAb to understand the likely 
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APPENDIX A: Study Population Approximation 
Calculations approximating study population using paid claims data from Medicaid and 





Total spending in 2019: $48,010,499 
Average spending per dosage unit: $559.84 
Doses per person, in one year: 12 
48,010,499 ÷ 559.84 = 85,758  




Medicare Part D 
Total spending in 2019: $119,459,268 
Average spending per dosage unit: $591.54 
Doses per person, in one year: 12 
119,459,268 ÷ 591.54 = 201,946  





Total spending in 2019: $23,788,338 
Average spending per dosage unit: $554.80 
Doses per person, in one year: 12 
23,788,338 ÷ 554.80 = 42,877  
42,877 ÷ 12 = 𝟑, 𝟓𝟕𝟑 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔  
 
Medicare Part D 
Total spending in 2019: $40,700,935 
Average spending per dosage unit: $588.61 
Doses per person, in one year: 12 
40,700,935 ÷ 588.61 = 69,147  





Total spending in 2019: $12,806,446 
Average spending per dosage unit: $373.95 
Doses per person, in one year: 12 
12,806,446 ÷ 373.95 = 34,246  















Medicare Part D 
Total spending in 2019: $28,888,525 
Average spending per dosage unit: $393.51 
Doses per person, in one year: 12 
28,888,525 ÷ 393.51 = 73,412  
73,412 ÷ 12 = 𝟔, 𝟏𝟏𝟕 𝒑𝒂𝒕𝒊𝒆𝒏𝒕s
Total number of patients covered by Medicaid or Medicare Part D in 2019 for a year 
supply of CGRP mAb migraine preventive 




APPENDIX B: Sample Informed Consent Form 
 
COMPOUND AUTHORIZATION AND CONSENT FORM FOR PARTICIPATION IN A 
RESEARCH STUDY 
YALE UNIVERSITY 
YALE UNIVERSITY SCHOOL OF MEDICINE, PHYSICIAN ASSOCIATE PROGRAM 
 
Study Title: EFFICACY OF RIMEGEPANT PLUS CALCITONIN GENE-RELATED 
PEPTIDE MONOCLONAL ANTIBODY FOR MIGRAINE 
 




You are being asked to join a research study. The following information will explain the purpose 
of the study, what you will be asked to do, and the potential risks and benefits. You should ask 





The purpose of this research study is to investigate the effectiveness of rimegepant (a medication 
indicated for treating acute migraine attacks) in the setting of use of a calcitonin gene-related 
peptide (CGRP) monoclonal antibody (erenumab, galcanezumab, fremanezumab, or 




This study involves 6 in-person visits over a 13-20 week time period. The first visit will include 
Safety Assessments: a physical examination, vital sign/ physical measurements, blood draws, an 
electrocardiogram (ECG), pregnancy test (if applicable), and questions about your migraine 
history of signs and symptoms. Then a Run-in Period (4 weeks) will begin during which you will 
use an electronic Patient Reported Outcomes (ePRO) Diary which will prompt you to document 
pain, symptoms, and adverse events at the time of a migraine attack (detailed explanation 
below). You may use your personal standard of care abortive treatments for each migraine attack 
during this period. Subjects who are unable to document appropriately may be excluded from 
further participation in the study. 
 
 Preparation and Primary Phase 
The second visit you will be asked to complete a Migraine-Specific Quality of Life 
Questionnaire (MSQ), a 14 item assessment that was developed to assess the effect of migraine 
on daily functioning. You will be randomly assigned to receive either a single dose (75 mg) of 
oral disintegrating rimegepant (Nurtec-ODT) or an identical placebo in a blister pack to be used 
to treat a single migraine attack of moderate or severe pain intensity. You and the researchers 
will not know which treatment you are assigned. This first phase of the study extends for a 
maximum of 8 weeks. Those who do not have a migraine attack during that period will be 
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dismissed from further participation in the study. Those who treat their single attack prior to the 
8 week mark may advance to the Secondary Phase. 
 
 Secondary Phase 
The third visit, after your first treated migraine attack, you will return for Safety Assessments. In 
the Secondary Phase of the study, you will receive rimegepant to treat multiple migraine attacks 
of moderate or severe pain intensity over an 8 week period. A blister pack containing twelve 75 
mg rimegepant tablets will be provided initially. Some subjects may have more frequent attacks 
than others and require more medication, so you will be instructed to notify the research 
pharmacy for more tablets if needed. You will have in-person visits at the end of weeks 2, 4, and 
8 during which Safety Assessments will be repeated and the MSQ will be administered  at the 4 
and 8 week visits. 
 
 ePRO Headache Diary 
At the time of a migraine attack, you will begin documentation in your ePRO Diary. The first 
question will be to rate your pain on a rating scale from 0-3, where 0 is no pain, 1 is mild pain, 2 
is moderate pain, and 3 is severe pain. If you rate your pain a 2 or 3 (moderate or severe) you 
will be asked additional questions via the ePRO Diary regarding specific symptoms (most 
bothersome symptom, nausea, light sensitivity, and sound sensitivity) before being prompted to 
take your pill (rimegepant or placebo) to treat the attack. After you take the pill, the ePRO Diary 
will prompt you to reevaluate your symptoms and pain at 30 minutes, 60 minutes, 90 minutes, 2 
hours, 3 hours, 4 hours, 8 hours, 12 hours, 24 hours. There will be an option to report side effects 
or other adverse events at any time during the study (and in the 30 days after you complete the 
study) and you will be encouraged to document them at the times they start and end (ePRO Diary 
will automatically timestamp the entries). 
 
Subjects who do not experience freedom from pain at 2 hours after taking the treatment or have 
unbearable pain prior to 2 hours will be allowed to use an approved rescue medication. This must 




There are some risks associated with participation in this study. These risks include (1) 
rimegepant, (2) phlebotomy, and (3) confidentiality. 
(1) Rimegepant 
 
Although uncommon, documented adverse reactions to rimegepant include nausea (2-
3%), abdominal pain (< 2%), dyspepsia (< 2%), and <1% risk of skin rash, 
hypersensitivity reaction, or dyspnea.1  
 







Possible risks associated with blood draws (as part of Safety Assessments) include pain, 
bleeding, fainting, bruising, infection, and/or hematoma at the injection site. 
 





Taking part in any research study places you at risk for loss of confidentiality. Several 
procedures are in place to reduce this risk (see below). 
 
1Nurtec ODT (rimegepant) [prescribing information]. New Haven, CT: Biohaven 




This research may benefit you directly in the treatment of your acute migraine attacks. Even if 
you do not directly benefit from taking part in the study (e.g., if you get placebo or rimegepant is 
not effective for you), the results will serve to improve our understanding of the effectiveness of 




To protect your confidentiality, your name and other identifying information will not be recorded 
on any study documents. At the time of enrollment, immediately after written informed consent 
is obtained and before performing any study-related procedures, you will be assigned a unique 4-
digit subject number for identification throughout the study. The method of blinding 
investigators and subjects as well as the collection and storage of health information obtained 
both in clinic and electronically will comply with all relevant privacy standards and regulations 
as written in the Health Insurance Portability and Accountability Act (HIPAA). We will only 
collect information that is needed for research. Only the researchers involved this study and 
those responsible for research oversight will have access to the information you provide. 
Examples of information that we are legally required to disclose include certain reportable 
diseases and Serious Adverse Events. 
 
Research Authorization: Except as permitted by law, your health information will not be 
released in an identifiable form outside of the Yale University research team. Examples of 
information that we are legally required to disclose include abuse of a child or elderly person, or 
certain reportable diseases. Note, however, that your records may be reviewed by those 
responsible for the proper conduct of research such as the Yale University Human Research 
Protection Program, Yale University Human Subjects Committee. The information about your 
health that will be collected in this study includes: age, gender, weight, height, race, admission 
diagnosis, medical comorbidities, length of hospital stay, infectious disease history, antibiotic 
use history and presence of indwelling devices. Information may be re-disclosed if the recipients 
are not required by law to protect the privacy of the information. At the conclusion of this study, 
any identifying information related to your research participation will be destroyed. By agreeing 
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to participate in this study, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose for the uses and disclosures you are authorizing is to 
ensure that the information relating to this research is available to all parties who may need it for 
research purposes. This authorization to use and disclose your health information collected 




Taking part in this study is your choice. You can choose to take part, or you can choose not to 
take part in this study. You can also change your mind at any time. Regardless of the choice you 
make, you will not lose access to your medical care or give up any legal rights or benefits. The 
researcher also has the right to discontinue your participation in the study at any time. Take as 
much time as you need before you make your decision. Ask the research staff any questions or to 
clarify items you do not understand. Once you have an understanding, you will be asked if you 




You have read the above description of the research study. You have read the risks and benefits 
involved, at this point please ask any further questions you have.  
 
If you have any further questions later or if you have a research-related problem, you may 
contact the Principal Investigator(s) at 203-xxx-xxxx. 
 
If you have questions about your rights as a research participant, or you have complaints about 
this research, you call the Yale Institutional Review Board at (203) 785-4688 or email 
hrpp@yale.edu.  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time. 
 
Authorization and Permission 
 
Your signature below indicates that you have read this consent document and that you agree to 
participate in this study. You will be provided with a copy of this form. 
 
___________________________  ___________________________  ______ 




___________________________  ___________________________  ______ 




Complete if the participant is not fluent in English and an interpreter was used to obtain consent. 
Participants who do not read or understand English must not sign this full consent form, but 
instead sign the short form translated into their native language. This form should be signed by 
the investigator and interpreter only. If the interpreter is affiliated with the study team, the 
signature of an impartial witness is also required. 
Print name of interpreter: __________________________________ 
Signature of interpreter: __________________________________   Date: _______ 
 
An oral translation of this document was administered to the participant in __________________ 
(language) by an individual proficient in English and __________________  (language). 
Print name of impartial witness: __________________________________ 








APPENDIX C: Phone Screening Questions 
 
“We would like to ask you some general information to determine whether you might qualify for 
this study. This information will only be used to determine your eligibility to participate in 
research. This information will be stored in secure research files. If you do not want any 
information about you stored, we will terminate this interview now. If you agree to proceed 
ahead with this preliminary interview and seem to be eligible to participate in this study, we may 
invite you for a face to face meeting. Would you like to continue?” 
YES/NO 
1. Verification of patient identifiers (name, date of birth) 
2. How old were you diagnosed with migraine? 
3. How many migraine attacks do you have per month? How many migraine attacks have 
you had per month for the last 3 months? 
4. Do you currently take or have you ever taken any of the following medications: 
erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), or eptinezumab 
(Vyepti)? 
a. If answer is yes: 
i. How long have you been taking the medication? 
ii. Has your dose changed in the past 3 months? 
iii. Do you use any other migraine preventives? How many? 
iv. What other medications or treatments do you take? 
b. If answer is no: 
i. Do you use any migraine preventives? How many? 
ii. What other medications or treatments do you take? 
5. Do you currently take a gepant (i.e. rimegepant, ubrogepant) to treat migraine attacks? 
6. Have you ever participated in an investigational study of a gepant? 
7. Have you participated in any other clinical investigation using an experimental drug or 
other therapy in the past 30 days? 
8. Women of childbearing potential  
a. Are you currently pregnant or breastfeeding? 
b. Are you planning to become pregnant in the next 6 months? 
9. May we have your verbal consent to access your medical records in order to further 
assess your eligibility for participation in this study? 
 
In addition to the phone screening questions above, the potential subjects’ medical records will 
be reviewed to determine eligibility based on inclusion/exclusion criteria. If met, they will be 





APPENDIX D: Recruitment Brochure 
 
DO YOU HAVE MIGRAINES? 
 





Have you NEVER taken erenumab, galcanezumab, fremanezumab, or 
eptinezumab? 
 
Volunteers Needed for Participation in a Research Study 
(read on for additional information) 
 
Study Purpose: To investigate the 
effectiveness of rimegepant (a medication 
for treating migraine attacks) with use of a 
CGRP monoclonal antibody (erenumab, 
galcanezumab, fremanezumab, or 
eptinezumab; for the prevention of migraine 
attacks). 
 
Who can participate? 
 
Adults (age 18-65 years) with at least 1 year 
history of migraine and treated for at least 3 
months with injectable anti-CGRP or anti-
CGRP mAb: erenumab (Aimovig), 
galcanezumab (Emgality), fremanezumab 




Adults (age 18-65 years) with at least a 1 
year history of migraine who have never 






If you are interested in 
participating or have any 
questions, please do not hesitate 





What will be asked of me? 
 
- You will be asked to take rimegepant 
(or placebo) to treat acute migraine 
attacks 
- Document your migraine symptoms 
in an electronic diary (or paper 
equivalent) 
- 6 in-person visits over a 13-20 week 
time period 
- Receive Safety Assessments: a 
physical examination, vital sign/ 
physical measurements, blood draws, 
an ECG, pregnancy test (if 
applicable), and answer questions 






APPENDIX E: Migraine Specific Quality of Life Questionnaire (MSQ) 
 
PATIENT INSTRUCTIONS: 
Please fill out this questionnaire. It will help us understand the effects of migraine headache on your daily 
activities. The questionnaire has been designed so that it can be completed quickly and easily. Please check only 
one answer for each question. You should answer every question. Thank you for your time. 
PLEASE SELECT ONLY ONE RESPONSE TO THESE QUESTIONS: 
1. In the past 4 weeks, how often have 
migraines interfered with how well you 
dealt with family, friends and others who 
are close to you? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
2. In the past 4 weeks, how often have 
migraines interfered with your leisure time 
activities, such as reading or exercising? 
(Select one response) 
3. In the past 4 weeks, how often have you had 
difficulty in performing work or daily activities 
because of migraine symptoms? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
4. In the past 4 weeks, how often did migraines 
 keep you from getting as much done at work or 
at home? 
(Select one response) 
 
  
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 
While answering the following questions, 





5. In the past 4 weeks, how often did 
migraines limit your ability to concentrate 
on work or daily activities? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
6. In the past 4 weeks, how often have 
migraines left you too tired to do work or 
daily activities? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
7. In the past 4 weeks, how often have 
migraines limited the number of days you 
have felt energetic? 
(Select one response) 
8. In the past 4 weeks, how often have you had 
to cancel work or daily activities because you 
had a migraine? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
9. In the past 4 weeks, how often did you need 
help in handling routine tasks. such as every 
day household chores, doing necessary 
business, shopping, or caring for others, when 
you had a migraine? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
10. In the past 4 weeks, how often did you have 
to stop work or daily activities to deal with 
migraine symptoms? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 






11. In the past 4 weeks, how often were you 
 not able to go to social activities such as 
parties or dinner with friends because you had 
a migraine? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
12. In the past 4 weeks, how often have you 
felt fed up or frustrated because of your 
migraines? 
(Select one response) 
13. In the past 4 weeks, how often have you felt 
like you were a burden on others because of 
your migraines? 
(Select one response) 
 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
14. In the past 4 weeks, how often have you 
been afraid of letting others down because of 
your migraines? 















 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 All of the time 
 None of the time 
 A little bit of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 





APPENDIX F: Safety Assessments 
 
Safety Assessments will be performed at the Screening Visit (Day -1), prior to the Run-in Period, 
after the first treated migraine attack in the Primary Phase, and at the end of weeks 2, 4, and 8 
during the Secondary Phase. 
 
1) Physical Examination 
2) Vital Signs/ Physical Measurements 
a. Height will only be captured at the Screening Visit. 
b. Weight (BMI), body temperature, respiratory rate, blood pressure, orthostatic 
change in blood pressure and heart rate will be collected at all indicated time 
points. 
3) Clinical Safety Laboratory Testing 
a. Hematology 
b. Blood chemistry/electrolytes 
c. Lipid panel 
d. LFTs, bilirubin 
e. eGFR 
f. Urinalysis 
g. Urine drug screen 
4) Electrocardiogram (ECG) 
5) Assessment of Migraine History (Signs and symptoms) 
6) Pregnancy Test 
a. A serum pregnancy test will be completed at the Screening Visit and at the 
conclusion of the Run-in Period (if appropriate). 
b. Confirmatory urine pregnancy test for Women of Child Bearing Potential 
(WOCBP) should be completed during remainder of indicated time points. 
7) Adverse Event (AE) and Serious Adverse Event (SAE) Assessment 
a. Definitions 
i. Serious Adverse Event (SAE)- any event that meets any of the following 
criteria: death, life-threatening, inpatient hospitalization or prolongation of 
existing hospitalization, persistent or significant disability/incapacity, 
congenital anomaly/birth defect in the offspring of a subject who received 
rimegepant, others may be considered an SAE when, based upon medical 
judgement, jeopardize the subject and may require medical or surgical 
intervention 
ii. Non-Serious Adverse Event (AE)- any unfavorable and unintended sign 
(e.g. abnormal laboratory finding), symptom, or disease temporally 
associated with the use of the investigational product, whether or not it is 
considered related to the investigational product 
b. SAEs are reported from the time of informed consent and non-serious AEs are 
reported from the time of first dose. All ongoing non-serious AEs and SAEs will 




status change. SAE and AE’s that occur during the treatment period should be 
reported to the site directly or via ePRO Diary. 
c. SAEs, whether related or not related to study drug, and pregnancies must be 











The sample size was calculated* using the following parameters: 
Alpha: 0.05 (tails = 2) 
Beta: 0.20 
Power of 80% 
Effect Size for proportions: 21.2% - 10.9% = 10.3% 
Factoring in a 7.1% drop out rate, the final sample size is 450 subjects, 225 in mAb group and 
225 in control group. 
 








1. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, 
double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241-254. 
2. Avona A, Burgos-Vega C, Burton MD, Akopian AN, Price TJ, Dussor G. Dural 
Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent 
Migraine Models. J Neurosci. 2019;39(22):4323-4331. 
3. Baker B, Schaeffler B, Cady R, Latham J, Whitaker T, Smith J. Rational Design of a 
Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), 
ALD403, Intended for the Prevention of Migraine (P2.155). Neurology. 2017;88(16 
Supplement):P2.155. 
4. Berman G, Croop R, Kudrow D, et al. Safety of Rimegepant, an Oral CGRP Receptor 
Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache: The Journal of 
Head and Face Pain. 2020;60(8):1734-1742 
5. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and 
sociodemographic factors: Results from the American migraine prevalence and 
prevention study. Headache. 2012;52(10):1456-1470. 
6. Centers for Medicare and Medicaid Services (CMS) Enterprise Portal- Medicare Part D 
Drugs. 2019. 
7. Centers for Medicare and Medicaid Services (CMS) Enterprise Portal- Medicaid Drugs. 
2019. 
8. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant 
orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, 
double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. 
9. De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting 
CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. 
Expert Review of Neurotherapeutics. 2020;20(6):627-641. 
10. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of 
migraine: CGRP and 5-HT beyond the triptans. Pharmacology and Therapeutics. 2020. 
11. Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients - a review of 
pros and cons. J Headache Pain. 2017;18(1):96-96. 
12. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in 
chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. 
Neurology. 2018;91(24):E2211-E2221. 
13. Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache 
Society for controlled trials of acute treatment of migraine attacks in adults: Fourth 
edition. Cephalalgia. 2019;39(6):687-710. 
14. Drug approvals and Databases. 2020; https://www.fda.gov/drugs/development-approval-
process-drugs/drug-approvals-and-databases, 2021. 
15. Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP Pathway for Acute and 
Preventive Treatment of Migraine: The Evolution of Success. Journal of Medicinal 
Chemistry. 2020. 
16. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine 
prevention in patients with documented failure to up to four migraine preventive 
medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b 




17. Gao B, Yang Y, Wang Z, et al. Efficacy and Safety of Rimegepant for the Acute 
Treatment of Migraine: Evidence From Randomized Controlled Trials. Front Pharmacol. 
2020;10:1577-1577. 
18. Gasparini S, Torino C, Branca D, Ferlazzo E, Aguglia U. Testing rimegepant for 
migraine—time to revise the trial design? The Lancet. 2020;395(10241):1901. 
19. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United 
States: A summary report and call to action. Annals of Neurology. 2017;81(4):479-484. 
20. Ha H, Gonzalez A. Migraine Headache Prophylaxis. Am Fam Physician. 2019;99(1):17-
24. 
21. Henson B, Hollingsworth H, Nevois E, Herndon C. Calcitonin Gene-Related Peptide 
(CGRP) Antagonists and Their Use in Migraines. J Pain Pall Care Pharmacother. 
2020;34(1):22-31. 
22. Insinga RP, Ng-Mak DS, Hanson ME. Costs associated with outpatient, emergency room 
and inpatient care for migraine in the USA. Cephalalgia. 2011;31(15):1570-1575. 
23. Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A. Coadministration of 
single therapeutic oral doses of ubrogepant and sumatriptan produces no clinically 
relevant pharmacokinetic interactions. Headache. 2019;59:86‐87. 
24. Ju C, Spiegel R, Radecki R, Swaminathan AK. Rimegepant in the Treatment of Migraine 
Headache: The Importance of Comparator Treatments: November 2019 Annals of 
Emergency Medicine Journal Club. Annals of Emergency Medicine. 2019;74(5):721-723. 
25. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic 
insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP 
antibody. Cephalalgia. 2019;39(10):1284-1297. 
26. Lipton RB, Croop R, Stock EG, et al. Rimegepant, an Oral Calcitonin Gene-Related 
Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142-149. 
27. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients 
with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365-e1377. 
28. Luo G, Chen L, Conway CM, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3-
difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-
1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral 
calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. 
J Med Chem. 2012;55(23):10644-10651. 
29. Maassen van den Brink A, Rubio-Beltrán E, Duncker D, Villalón CM. Is CGRP Receptor 
Blockade Cardiovascularly Safe? Appropriate Studies Are Needed. Headache: The 
Journal of Head and Face Pain. 2018;58(8):1257-1258. 
30. Mahmoud AA, Salah S. Fast relief from migraine attacks using fast-disintegrating 
sublingual zolmitriptan tablets. Drug Dev Ind Pharm. 2012;38(6):762-769. 
31. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the 
acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-
ranging trial. Cephalalgia. 2014;34(2):114-125. 
32. Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule 
CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 
2020;94(20):e2121-e2125. 
33. Paying for Aimovig. 2020; https://www.aimovig.com/paying-for-aimovig. Accessed July 




34. Ramón C, Cernuda-Morollón E, Pascual J. Calcitonin gene-related peptide in peripheral 
blood as a biomarker for migraine. Curr Opin Neurol. 2017;30(3):281-286. 
35. Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF. The psychometric properties of 
the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic 
migraine patients. Quality of Life Research. 2013;22(5):1123-1133. 
36. Robblee J, Starling AJ. SEEDS for success: Lifestyle management in migraine. 
Cleveland Clinic Journal of Medicine. 2019;86(11):741-749. 
37. Rubio-Beltran E, Chan KY, Danser AJ, MaassenVanDenBrink A, Edvinsson L. 
Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant 
and atogepant in human isolated coronary, cerebral and middle meningeal arteries. 
Cephalalgia. 2020;40(4):357-366. 
38. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: A documentation 
of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210. 
39. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive 
treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 
trial. The Lancet Neurology. 2017;16(6):425-434. 
40. Ziegeler C, May A. Non-Responders to Treatment With Antibodies to the CGRP-
Receptor May Profit From a Switch of Antibody Class. Headache: The Journal of Head 
and Face Pain. 2020;60(2):469-470. 
 
